Skip to content
Clinical Trial Events
19th Clinical Trials on Alzheimer's Disease (CTAD) 2026

Talk

Oral Communications

Wed, Nov 18, 2026 · 11:40 AM–12:25 PM EST Ballroom - 4th floor, Boston Marriott Copley Place

About this session

Oral communications: OC26 Using Plasma P-tau217 and APOE Genotype to Predict Onset of Symptoms of Alzheimer's Disease; OC27 AAV2-BDNF Gene Therapy in Alzheimer's Disease and Mild Cognitive Improvement Improves FDG-PET in Memory Circuitry; OC28 Leveraging the Global Neurodegeneration Proteomics Consortium Dataset to Identify Plasma Proteomic Profiles Associated with Alzheimer's Disease Progression and Biological Endotypes.

Speakers